Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Analyst Ratings
Strong Buy
13 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BPMC Stock 12 Month Forecast
Average Price Target
$127.94
▲(31.67% Upside)
| Highest Price Target$155.00 | Average Price Target$127.94 | Lowest Price Target$93.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
05/02/25
Leerink Partners
Reiterated
05/02/25
Morgan Stanley
Reiterated
05/01/25
J.P. Morgan
$129→$130
Buy
33.79%
Upside
Reiterated
05/01/25
Analysts Conflicted on These Healthcare Names: Blueprint Medicines (NASDAQ: BPMC), Envista Holdings (NYSE: NVST) and Hologic (NASDAQ: HOLX)
Wedbush
$128
Buy
31.73%
Upside
Reiterated
04/16/25
Blueprint Medicines (BPMC) Receives a Buy from Wedbush
Jefferies
$135
Buy
38.93%
Upside
Reiterated
04/15/25
Blueprint Medicines: A Defensive Biotech with Strong Growth Potential and M&A Appeal
Wolfe Research
$132
Buy
35.84%
Upside
Reiterated
03/31/25
Optimistic Long-Term Growth Potential for Blueprint Medicines Amid Short-Term Revenue Concerns
Piper Sandler
$119
Hold
22.47%
Upside
Reiterated
03/17/25
Piper Sandler Remains a Hold on Blueprint Medicines (BPMC)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
05/02/25
Leerink Partners
Reiterated
05/02/25
Morgan Stanley
Reiterated
05/01/25
J.P. Morgan
$129→$130
Buy
33.79%
Upside
Reiterated
05/01/25
Analysts Conflicted on These Healthcare Names: Blueprint Medicines (NASDAQ: BPMC), Envista Holdings (NYSE: NVST) and Hologic (NASDAQ: HOLX)
Wedbush
$128
Buy
31.73%
Upside
Reiterated
04/16/25
Blueprint Medicines (BPMC) Receives a Buy from Wedbush
Jefferies
$135
Buy
38.93%
Upside
Reiterated
04/15/25
Blueprint Medicines: A Defensive Biotech with Strong Growth Potential and M&A Appeal
Wolfe Research
$132
Buy
35.84%
Upside
Reiterated
03/31/25
Optimistic Long-Term Growth Potential for Blueprint Medicines Amid Short-Term Revenue Concerns
Piper Sandler
$119
Hold
22.47%
Upside
Reiterated
03/17/25
Piper Sandler Remains a Hold on Blueprint Medicines (BPMC)
Best Analysts Covering Blueprint Medicines
Which Analyst Should I Follow If I Want to Buy BPMC and Sell After:
1 Month
xxx
Success Rate
10/16 ratings generated profit
Average Return
+2.90%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +2.90% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
Average Return
+9.64%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +9.64% per trade.
1 Year
Success Rate
14/16 ratings generated profit
Average Return
+17.54%
reiterated a buy rating 11 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +17.54% per trade.
2 Years
xxx
Success Rate
15/16 ratings generated profit
Average Return
+24.03%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +24.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BPMC Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
3
4
6
8
5
Buy
10
17
20
16
14
Hold
9
11
13
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
32
39
33
27
Each month's total comprises the sum of three months' worth of ratings.
BPMC Financial Forecast
BPMC Stock Forecast FAQ
What is BPMC’s average 12-month price target, according to analysts?
Based on analyst ratings, Blueprint Medicines’s 12-month average price target is 127.94.
What is BPMC’s upside potential, based on the analysts’ average price target?
Blueprint Medicines has 31.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BPMC a Buy, Sell or Hold?
Blueprint Medicines has a consensus rating of Strong Buy which is based on 13 buy ratings, 4 hold ratings and 0 sell ratings.
What is Blueprint Medicines’s price target?
The average price target for Blueprint Medicines is 127.94. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $155.00 ,the lowest forecast is $93.00. The average price target represents 31.67% Increase from the current price of $97.17.
The highest analyst price target is $155.00 ,the lowest forecast is $93.00. The average price target represents 31.67% Increase from the current price of $97.17.
What do analysts say about Blueprint Medicines?
Blueprint Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of BPMC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.